×

Sarepta CEO 'optimistic' for muscle drug approval

2:07 PM ET Mon, 21 April 2014

Sarepta Therapeutics CEO Chris Garabedian discusses the prospects for what he calls a "potential accelerated approval" for its Duchenne muscular dystrophy drug Eteplirsen.